-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

Benzinga·08/19/2026 12:43:25
Listen to the news
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.